Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Period	TotalRevenue
2018-12-31	$14.32M
2019-12-31	$42.98M
2020-12-31	$21.80M
2021-12-31	$53.60M
2022-12-31	$131.40M
2023-12-31	$78.50M
2024-12-31	$263.40M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARVN	$11.18	-1.67%	0.48M
3
4
5

Arvinas Inc. (ARVN) Revenue History

Revenue Data

Get Arvinas Inc. Data in Excel

More ARVN Financial Data